News & Updates

New Clinical Data Supports Viz.ai Solution for Improved Pulmonary Embolism Detection and Care Coordination

10/03/2023

Company’s Artificial Intelligence Technology Shows Better Results in Early Detection and Patient Care Excerpt from the Press Release: SAN FRANCISCO–(BUSINESS WIRE)–Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in pulmonary embolism (PE) detection. Two studies have demonstrated the real-world clinical efficacy of Viz.ai’s PE Module…

Aligos Therapeutics Announces IND Clearance for NASH lead, ALG-055009

10/02/2023

– Phase 2a NASH protocol on track to be submitted to the IND in Q4 2023, enrollment expected to begin in Q1 2024 Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to…

Meet with Christopher Kata and the TrialStat team at the TrialStat team during the “SoCalBio 25th Annual Conference” October 26th to 27th!

10/02/2023

Christopher Kata and the TrialStat team are attend this years “SoCalBio 25th Annual Conference” meeting on October 25th through the 26th in Long Beach, California. If you’re attending be sure to to reach out to Christopher to schedule a one on meeting! We’re looking forward to meeting with you and providing live, personalized demonstrations of…

Datopotamab deruxtecan demonstrated statistically significant and clinically meaningful progression-free survival benefit in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial

09/29/2023

First Phase III results in breast cancer for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan Plans for global regulatory submissions underway Excerpt from the Press Release: WILMINGTON, Del.–(BUSINESS WIRE)–Positive high-level results from the TROPION-Breast01 Phase III trial showed datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant and clinically meaningful improvement for the primary endpoint of progression-free survival…

Via Nova Therapeutics Announces FDA clearance of Investigational New Drug (IND) application for VNT-101, a novel direct-acting antiviral against Influenza A virus

09/28/2023

Excerpt from the Press Release: OAKLAND, Calif., Sept. 21, 2023 /PRNewswire/ — Via Nova Therapeutics, Inc., a biotechnology company focused on discovering and developing therapeutics to treat viral infections with significant unmet medical need, today announced the clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for its…

UCSF QBI, University College London, and Mount Sinai Identify Shared Molecular Mechanisms Across SARS-CoV-2 Variants that Allow Virus to Thrive Despite Vaccination

09/27/2023

– Findings show viral proteins outside of Spike across Alpha, Beta, Gamma, Delta and Omicron SARS-CoV-2 variants are responsible for innate immune suppression and escape from human immune system barriers – Elucidation of common evolutionary thread provides key biologic target against future COVID-19 variants and other pandemics Excerpt from the Press Release: SAN FRANCISCO and…

Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)

09/26/2023

Excerpt from the Press Release: MALVERN, Pa., Sept. 13, 2023 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced a clinical study update for Retinitis Pigmentosa (RP) participants treated in the Phase 1/2 trial…

Vincerx Pharma Doses First Patient in the Phase 1 Clinical Trial Evaluating VIP943

09/25/2023

Phase 1 trial enrolling patients with relapsed/refractory AML, MDS and B-cell ALL Excerpt from the Press Release: PALO ALTO, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) — Vincerx Pharma, Inc. (Nasdaq: VINC)(“Vincerx”), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported that the first patient has been…

Meet with Christopher Kata and the TrialStat team at the “Octane Medical Innovations Forum (MIF)” October 25th to 26th!

09/25/2023

Christopher Kata and the TrialStat team are attend this years “Octane Medical Innovations Forum” meeting on October 25th through the 26th in Irvine, California. If you’re attending be sure to to reach out to Christopher to schedule a one on meeting! We’re looking forward to meeting with you and providing live, personalized demonstrations of our…

Charles River and Related Sciences Enter Multi-Program Collaboration to Pursue AI-Enabled Drug Discovery Utilizing Logica

09/22/2023

Logica, an offering from Charles River and Valo Health, will be used to discover first-in-class therapeutics against high value targets in the Related Sciences portfolio Excerpt from the Press Release: WILMINGTON, Mass. & DENVER–(BUSINESS WIRE)–Charles River Laboratories International, Inc. (NYSE: CRL) and Related Sciences (“RS”), a data science-driven drug discovery firm, today announced a multi-program…

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

A New Paradigm in eClinical Technology